PMID- 12490778
OWN - NLM
STAT- MEDLINE
DCOM- 20030117
LR  - 20190713
IS  - 0041-1337 (Print)
IS  - 0041-1337 (Linking)
VI  - 74
IP  - 11
DP  - 2002 Dec 15
TI  - Isolation of precursor endothelial cells from peripheral blood for donor-specific 
      crossmatching before organ transplantation.
PG  - 1479-86
AB  - BACKGROUND: The clinical importance of endothelial-cell (EC) antibodies (Abs) in 
      allo-transplantation (Tx) has been reported. However, lack of a suitable method 
      for isolation of donor-specific ECs has prevented routine detection of these Abs 
      before Tx. We describe a quick and simple method for the direct isolation of ECs 
      from whole blood, for routine crossmatching (XM) to detect anti-EC Abs. METHODS: 
      ECs were isolated using magnetic beads coated with Abs against the angiopoietin 
      receptor Tie-2 that is expressed on EC precursors. A retrospective analysis of 50 
      previously well-characterized XM sera taken immediately before transplantation 
      from patients with end-stage kidney disease were tested. RESULTS: Tie-2+ cells 
      expressed human leukocyte antigen (HLA) class I, class II, and other EC markers. 
      Sera known to contain only EC-specific or EC- and monocyte (EM)-reactive Abs 
      reacted positively with Tie-2+ cells but not with Tie-2- cells from the same 
      individual. In addition, the Tie-2+ cells reacted with sera containing only HLA 
      class I or class II Abs. In all, 3 of 25 sera from patients with stable graft 
      outcome and no rejections reacted with Tie-2+ cells. CONCLUSIONS: For the first 
      time, with use of a single-target cell population, the detection of clinically 
      relevant donor-specific HLA class I, class II, EM, and EC-specific Abs can be 
      performed routinely before Tx. This method is promising because it is quick, 
      specific, and easy to perform on whole blood samples and can therefore be used to 
      perform routine donor-specific EC crossmatching (ECXM) in the future. Routine use 
      of ECXM will aid in identifying better donor-recipient combinations and thus have 
      a greater impact on transplant survival as compared with lymphocyte crossmatch 
      (LXM).
FAU - Vermehren, Dilki
AU  - Vermehren D
AD  - Division of Clinical Immunology, Huddinge University Hospital, Karolinska 
      Institutet, Stockholm, Sweden.
FAU - Sumitran-Holgersson, Suchitra
AU  - Sumitran-Holgersson S
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (Antibodies)
RN  - 0 (Biomarkers)
RN  - 0 (MEN1 protein, human)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Proto-Oncogene Proteins)
RN  - EC 2.7.10.1 (Receptor, TIE-2)
SB  - IM
MH  - Antibodies/analysis
MH  - Biomarkers/analysis
MH  - Blood Cells/chemistry
MH  - *Cell Separation
MH  - Endothelium, Vascular/chemistry/*cytology/immunology
MH  - Flow Cytometry
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Immunohistochemistry
MH  - Monocytes/chemistry/cytology
MH  - Neoplasm Proteins/analysis
MH  - *Organ Transplantation
MH  - *Proto-Oncogene Proteins
MH  - Receptor, TIE-2
MH  - Retrospective Studies
MH  - *Stem Cells/chemistry
MH  - *Tissue Donors
EDAT- 2002/12/20 04:00
MHDA- 2003/01/18 04:00
CRDT- 2002/12/20 04:00
PHST- 2002/12/20 04:00 [pubmed]
PHST- 2003/01/18 04:00 [medline]
PHST- 2002/12/20 04:00 [entrez]
AID - 10.1097/00007890-200212150-00001 [doi]
PST - ppublish
SO  - Transplantation. 2002 Dec 15;74(11):1479-86. doi: 
      10.1097/00007890-200212150-00001.